1 week Ago By ABMN Staff
Norges Bank purchased a new position in shares of Taysha Gene Therapies, Inc. ( NASDAQ:TSHA – Free Report ) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,461,120 shares of the company’s stock, valued at approximately $2,528,000.
Several other hedge funds also recently modified their holdings of TSHA. EntryPoint Capital LLC boosted its position in Taysha Gene Therapies by 127.5% during the fourth quarter.
EntryPoint Capital LLC now owns 61,495 shares of the company’s stock worth $106,000 after acquiring an additional 34,468 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Taysha Gene Therapies by 7.
8% during the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company’s stock worth $15,409,000 after purchasing an additional 641,305 shares during the period.
LPL Financial LLC purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at $104,000. AXQ Capital LP acquired a new position in Taysha Gene Therapies in the fourth quarter valued at $39,000. Finally, Virtu Financial LLC acquired a new position in Taysha Gene Therapies in the fourth quarter valued at $186,000.
77.70% of the stock is owned by institutional investors and hedge funds. Taysha Gene Therapies Stock Performance NASDAQ TSHA opened at $1.
25 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.
51 and a quick ratio of 5.51. Taysha Gene Therapies, Inc.
has a 1-year low of $1.05 and a 1-year high of $4.32.
The business’s 50-day simple moving average is $1.58 and its 200-day simple moving average is $1.84.
The firm has a market capitalization of $255.23 million, a P/E ratio of 1.98 and a beta of 0.
96. Wall Street Analysts Forecast Growth A number of research analysts have recently commented on TSHA shares. Chardan Capital reaffirmed a “buy” rating and set a $7.
00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Thursday.
Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $6.63.
Check Out Our Latest Research Report on TSHA Taysha Gene Therapies Profile ( Free Report ) Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Featured Stories Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. ( NASDAQ:TSHA – Free Report ). Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.
com's FREE daily email newsletter ..
